Trafermin
Star0
This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.
Identification
- Generic Name
- Trafermin
- DrugBank Accession Number
- DB06244
- Background
Not Available
- Type
- Biotech
- Groups
- Investigational
- Biologic Classification
- Protein Based Therapies
Other protein based therapies - Protein Chemical Formula
- Not Available
- Protein Average Weight
- Not Available
- Sequences
- Not Available
- Synonyms
- Recombinant human basic fibroblast growth factor
- rhbFGF
- Trafermin
- External IDs
- CAB-2001
Pharmacology
- Indication
Investigated for use/treatment in coronary artery disease, peripheral vascular disease, periodontal disease, bone fractures, entero-related fistulae, and diabetic foot ulcers.
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Contraindications & Blackbox Warnings
- Prevent Adverse Drug Events TodayTap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events with our Clinical API
- Pharmacodynamics
Not Available
- Mechanism of action
Trafermin, or basic fibroblast growth factor 2 (bFGF) is a recombinant human growth factor used to stimulate angiogenesis and keratinization in wound healing. It stimulates migration of monocytes, neutrophils, macrophages, fibroblasts and also assists in creation of granulation tissue (the tissue that replaces fibrin clots in healing wounds).
- Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
- Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!Improve decision support & research outcomes with our structured adverse effects data.
- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.Not Available
- Food Interactions
- Not Available
Products
- Drug product information from 10+ global regionsOur datasets provide approved product information including:dosage, form, labeller, route of administration, and marketing period.Access drug product information from over 10 global regions.
- International/Other Brands
- Fiblast (Kaken Pharmaceuticals Co., Ltd.)
Categories
- ATC Codes
- D03AX15 — Trafermin
- Drug Categories
- Chemical TaxonomyProvided by Classyfire
- Description
- Not Available
- Kingdom
- Organic Compounds
- Super Class
- Organic Acids
- Class
- Carboxylic Acids and Derivatives
- Sub Class
- Amino Acids, Peptides, and Analogues
- Direct Parent
- Peptides
- Alternative Parents
- Not Available
- Substituents
- Not Available
- Molecular Framework
- Not Available
- External Descriptors
- Not Available
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- 333OX80X87
- CAS number
- 131094-16-1
References
- General References
- Yamaguchi S, Asao T, Nakamura J, Tsuboi K, Tsutsumi S, Kuwano H: Effect of basic fibroblast growth factor, trafermin, on entero-related fistulae, report of two cases. Hepatogastroenterology. 2007 Apr-May;54(75):803-5. [Article]
- Bogousslavsky J, Victor SJ, Salinas EO, Pallay A, Donnan GA, Fieschi C, Kaste M, Orgogozo JM, Chamorro A, Desmet A: Fiblast (trafermin) in acute stroke: results of the European-Australian phase II/III safety and efficacy trial. Cerebrovasc Dis. 2002;14(3-4):239-51. [Article]
- External Links
- Wikipedia
- FGF2
Clinical Trials
- Clinical Trials
Phase Status Purpose Conditions Count 3 Completed Treatment Bone Loss, Alveolar / Periodontal Attachment Loss / Periodontitis 1 3 Completed Treatment Diabetic Foot Ulcer of Neuropathic Origin 2 3 Completed Treatment Periodontitis 1 3 Completed Treatment Tympanic Membrane Perforation 1 2 Completed Treatment Periodontitis 2
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
- Not Available
- Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Solid
- Experimental Properties
- Not Available
Drug created at March 19, 2008 16:19 / Updated at February 21, 2021 18:52